Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy
Paola Queirolo, Pietro Quaglino(Department of Medical Sciences), Enrica T. Tanda(Ospedale Policlinico San Martino), Francesco Spagnolo(Martin University), Andrea Boutros(The University of Sydney)
Cited by 119
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2017|491
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
|JAMA Dermatology|2015|452